Dr. OlgaBezzubova


Munich +

Dr. Olga Bezzubova has nearly 20 years of experience in obtaining and defending intellectual property rights for clients in the fields of pharmaceuticals, biotechnology, and diagnostics. She advises on all aspects of patent prosecution and opposition, patent validity, and infringement. Olga's training in physics and biology allows her to counsel clients in matters involving various aspects of cell biology, genomics, proteomics, molecular biology, food science, biopharmaceuticals, and biophysics, as well as emerging technologies at the convergence of biological and physical sciences.

Olga received her Ph.D. at the Basel Institute of Immunology (BII) in Switzerland with a focus on immunoglobulin gene rearrangements. This unique experience allows her a particular insight into matters relating to immunology with focus on antibodies and similar areas. Olga has represented clients in highly competitive areas of RNA interference (RNAi) and CRISPR/Cas.

Olga's practice also includes performing patent invalidity, noninfringement and freedom-to-operate analyses, and conducting patent portfolio for clients, including potential investors, acquirers, and licensees. She also has experience in providing strategic advice and managing worldwide patent portfolios of established biotech companies as well as start-ups. Close work with her U.S. colleagues provides Olga with insight into USPTO patent prosecution and inter partes review (IPR) proceedings.

Olga has authored and coauthored numerous publications in the field of molecular genetics and IP. She also has taught IP classes at the Institute for Machine Tools and Business Sciences (IWB) at the Technical University in Munich.


  • Celgene acquired by Bristol-Myers Squibb for approximately $74 billionJones Day advised Celgene Corporation (NASDAQ: CELG) in connection with the intellectual property and technology transactions aspects of its cash-and-stock merger with Bristol-Myers Squibb (NYSE: BMY) which has an equity value of approximately $74 billion.
  • Celgene develops European patent portfolio covering protein-bound nanoparticle technology (Nab®)Jones Day represented Celgene Corporation in successfully obtaining numerous European patents relating to one of its platform technologies, namely protein-bound nanoparticles (Nab®).
  • CJ CheilJedang defends German patent infringement action by Japanese competitorJones Day is representing CJ CheilJedang Corporation, a major Korean-based multinational company, in a patent dispute with a Japanese competitor before the courts in Germany.
  • ToolGen seeks patent protection for CRISPR technologyJones Day is prosecuting patent applications and developing a patent portfolio on behalf of ToolGen, Inc. for CRISPR technology.
  • Celgene subsidiary develops patent portfolio for stem cell and biofabric productsOn behalf of Celgene Cellular Therapeutics, a wholly owned subsidiary of Celgene Corporation, Jones Day assisted with patent prosecution strategies and establishing patent portfolios for the stem cell and biofabric products being developed by the company.
  • Speaking Engagements

    • February 7, 2017
      Brexit and the Unitary Patent System, JD Women in IP
    • November 19, 2013
      IP Strategies for Life Science Companies: The New European System, Seminar for France Biotech
    • June 4, 2013
      Divisionals in Europe: Practical Advice
    • March 25, 2013
      Europe's New Unitary Patent and Unified Patent Court: How the introduction of the Unitary Patent and Unified Patent Court will impact your existing patent portfolio
    We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.